Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic <i>NF2</i> -Deficient Meningiomas
AG-NF2-Men represents the first NF2-SWN-related meningioma model. The brigatinib + INK128 combination exhibits antitumor synergy in both the AG-NF2-Men and Ben-Men-1 meningioma models, suggesting combining brigatinib with mTOR inhibition to more effectively treat NF2-SWN and sporadic NF2-deficient meningiomas.
Authors
- Janet L. Oblinger (ORCID: https://orcid.org/0000-0001-6044-5624)
- Long‐Sheng Chang (ORCID: https://orcid.org/0000-0002-5178-2992)
- Lai Man Natalie Wu (ORCID: https://orcid.org/0000-0002-7285-3606)
- Cecelia Miller (ORCID: https://orcid.org/0000-0001-6110-6069)
- Sarah S. Burns (ORCID: https://orcid.org/0000-0002-6907-2366)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Nationwide Children's Hospital (US)
- The Ohio State University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0563
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- CancerFree KIDS